Objective:

To evaluate the clinical value of salvage stereotactic radiotherapy (SRT) in HER2-positive breast cancer patients with brain metastases after TKI therapy.

Approach:

Key Findings:

• Median follow-up duration was 10.7 months.
• Median poRT-iPFS was 6.4 months.
• Median NEST was 5.2 months.
• Median OS was 9.5 months.
• MRI-SD group had a significantly longer median poRT-iPFS (7.9 months) compared to MRI-PD group (5.5 months; P < 0.001).
• Main grade ≥3 treatment-related adverse events included diarrhoea (20%), anaemia (20%), leucopenia (18%), nausea (15%), and thrombocytopenia (13%).

Interpretation:

Limitations:

• Single-center study may limit generalizability.
• Retrospective design may introduce selection bias.

Conclusion:

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.